XML 30 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Stock Based Compensation
9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Payment Arrangement

NOTE 14: STOCK BASED COMPENSATION

On May 15, 2020, the stockholders of the Company approved the 2020 Stock Incentive Plan (the 2020 Plan) to provide for the grants of equity-based awards to employees, officers, non-employee directors and other key persons providing services to the Company. On June 27, 2024, the stockholders of the Company approved an amendment and restatement of the 2020 Plan which increased the shares available for issuance by 12,000,000 shares, to a total of 30,000,000 shares available for grant. The 2020 Plan was also extended through June 27, 2034. As of September 30, 2024, 13,484,925 shares were available for future grants under the 2020 Plan.

 

The Company recognized stock-based compensation expense in the Condensed Consolidated Statements of Operations as follows (in thousands):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Research and development

 

$

204

 

 

$

324

 

 

$

440

 

 

$

1,289

 

General and administrative

 

 

545

 

 

 

602

 

 

 

1,078

 

 

 

2,813

 

Total stock-based compensation expense

 

$

749

 

 

$

926

 

 

$

1,518

 

 

$

4,102

 

 

 

The following table shows a summary of all stock option activity for the nine months ended September 30, 2024:

 

 

Number of
Underlying
Shares

 

 

Weighted-
Average
Exercise Price
Per Share

 

 

Weighted-
Average
Contractual
Life
Remaining
in Years

 

 

Aggregate
Intrinsic Value

 

Outstanding as of January 1, 2024

 

 

17,506,345

 

 

$

1.79

 

 

 

 

 

$

554,525

 

Granted

 

 

4,208,334

 

 

 

1.06

 

 

 

 

 

 

 

Forfeited

 

 

(1,167,504

)

 

 

1.60

 

 

 

 

 

 

 

Exercised

 

 

(343,998

)

 

 

0.79

 

 

 

 

 

 

 

Expired

 

 

(4,606

)

 

 

258.08

 

 

 

 

 

 

 

Outstanding as of September 30, 2024

 

 

20,198,571

 

 

$

1.61

 

 

 

7.13

 

 

$

6,090,201

 

Exercisable as of September 30, 2024

 

 

16,069,778

 

 

$

1.76

 

 

 

6.53

 

 

$

3,966,111

 

Vested and expected to vest

 

 

20,198,571

 

 

$

1.61

 

 

 

7.13

 

 

$

6,090,201

 

 

No options were granted during the three months ended September 30, 2024. The weighted average grant date fair value of options granted during the nine months ended September 30, 2024 was $0.84.

 

As of September 30, 2024, the unrecognized compensation cost associated with unvested options was $3.1 million. This expense is expected to be recognized over a weighted-average period of 1.49 years.